{"hands_on_practices": [{"introduction": "Before designing a CRISPR experiment, a fundamental question must be answered: how many potential target sites are even available in the genome? The ability of Cas9 to bind and cut DNA is not just dependent on the guide RNA sequence but also on the presence of a specific, short sequence next to the target called the Protospacer Adjacent Motif (PAM). This exercise [@problem_id:2802366] demonstrates how we can use basic probability and known genomic properties, like GC content, to estimate the frequency of these essential PAM sites across a genome, giving us a first-pass assessment of the technology's targeting potential.", "problem": "A widely used endonuclease in clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) genome editing is the Streptococcus pyogenes Cas9 (SpCas9), which requires the presence of a Protospacer Adjacent Motif (PAM) with sequence motif \"NGG\" immediately downstream of the target site on the non-target strand. Consider a large double-stranded genome of length $L$ base pairs whose nucleotide composition is stationary and independent across positions, with guanine-cytosine (GC) fraction $g$. Assume Chargaff parity so that the marginal base frequencies on a single strand are $\\Pr(G)=\\Pr(C)=g/2$ and $\\Pr(A)=\\Pr(T)=(1-g)/2$, and assume strand symmetry and independence across adjacent positions. Throughout, count PAMs on a single designated strand only; do not double-count reverse complements. Ignore end effects, treating the number of length-$3$ windows as $L$ for large $L$.\n\n1. Starting only from these assumptions and the product rule for independent events, derive an expression in terms of $g$ for the expected per-base frequency of windows equal to the PAM motif \"NGG\" on the designated strand.\n2. Using your expression, compute the expected number of \"NGG\" PAM sites in a genome of length $L=3\\times 10^{9}$ base pairs when $g=0.41$.\n\nExpress the final count as a pure number of PAM sites in scientific notation, and round your answer to three significant figures. Do not include units in your final answer.", "solution": "The problem as stated will first be subject to rigorous validation.\n\n**Problem Validation**\n\nThe givens are extracted verbatim for analysis.\n-   **System**: CRISPR-Cas9 genome editing, specifically with *Streptococcus pyogenes* Cas9 (SpCas9).\n-   **Motif**: The Protospacer Adjacent Motif (PAM) has the sequence \"NGG\".\n-   **Genome Length**: $L$ base pairs.\n-   **Probabilistic Model**:\n    -   Nucleotide composition is stationary and independent across positions.\n    -   Guanine-cytosine (GC) fraction is $g$.\n    -   Single-strand marginal base probabilities are $\\Pr(G)=\\Pr(C)=g/2$ and $\\Pr(A)=\\Pr(T)=(1-g)/2$.\n-   **Assumptions and Constraints**:\n    -   Counting is restricted to a single designated strand.\n    -   End effects are ignored; the number of length-$3$ windows is approximated as $L$.\n-   **Parameters for Calculation**: $L=3\\times 10^{9}$ and $g=0.41$.\n\nThis problem is scientifically grounded. The \"NGG\" PAM for SpCas9 is a fundamental fact in the field of gene editing. The probabilistic model, assuming independent and identically distributed nucleotides, is a standard and useful first-order approximation in bioinformatics for estimating sequence motif frequencies. The provided parameters for genome length and GC content are realistic for the human genome. The problem is well-posed, with all necessary information provided and no internal contradictions. The instructions are clear and unambiguous. The problem is formalizable and requires direct application of probability theory. Thus, the problem is deemed **valid**.\n\n**Solution Derivation**\n\nThe solution proceeds in two parts, as requested.\n\n**Part 1: Derivation of PAM Frequency Expression**\n\nThe problem requires the derivation of the expected per-base frequency of the \"NGG\" PAM motif. This is equivalent to finding the probability, $P_{\\text{NGG}}$, that a randomly selected window of length $3$ on the designated strand has the sequence \"NGG\".\n\nThe model assumes that nucleotides at different positions are independent. Therefore, the probability of a specific sequence is the product of the probabilities of the individual nucleotides at each position. The PAM motif is a sequence of three nucleotides: the first is 'N' (any nucleotide), the second is 'G' (guanine), and the third is 'G' (guanine).\n\nThe probability of the first nucleotide being 'N' is the sum of the probabilities of it being 'A', 'T', 'C', or 'G'.\n$$ \\Pr(N) = \\Pr(A) + \\Pr(T) + \\Pr(C) + \\Pr(G) $$\nUsing the provided single-strand probabilities in terms of the GC fraction $g$:\n$$ \\Pr(A) = \\frac{1-g}{2} $$\n$$ \\Pr(T) = \\frac{1-g}{2} $$\n$$ \\Pr(C) = \\frac{g}{2} $$\n$$ \\Pr(G) = \\frac{g}{2} $$\nSubstituting these into the expression for $\\Pr(N)$:\n$$ \\Pr(N) = \\frac{1-g}{2} + \\frac{1-g}{2} + \\frac{g}{2} + \\frac{g}{2} = \\frac{(1-g) + (1-g) + g + g}{2} = \\frac{2-2g+2g}{2} = \\frac{2}{2} = 1 $$\nAs expected, the probability of observing any nucleotide at a position is $1$.\n\nThe probability of the \"NGG\" motif at any given $3$-base window is thus:\n$$ P_{\\text{NGG}} = \\Pr(N) \\times \\Pr(G) \\times \\Pr(G) $$\nSubstituting the known probabilities:\n$$ P_{\\text{NGG}} = 1 \\times \\left(\\frac{g}{2}\\right) \\times \\left(\\frac{g}{2}\\right) = \\frac{g^2}{4} $$\nThis expression represents the expected per-base frequency of the \"NGG\" PAM motif.\n\n**Part 2: Calculation of Expected Number of PAM Sites**\n\nThe problem asks for the expected number of \"NGG\" PAM sites, which we denote as $E[N_{\\text{NGG}}]$, in a genome of length $L$. We are instructed to approximate the number of possible starting positions for a $3$-base window as $L$.\n\nLet $I_i$ be an indicator random variable for each starting position $i$ from $1$ to $L$. $I_i=1$ if the window starting at position $i$ is \"NGG\", and $I_i=0$ otherwise. The expected value of this indicator variable is the probability of the event:\n$$ E[I_i] = \\Pr(I_i=1) = P_{\\text{NGG}} = \\frac{g^2}{4} $$\nThe total number of \"NGG\" sites, $N_{\\text{NGG}}$, is the sum of these indicator variables over all possible starting positions:\n$$ N_{\\text{NGG}} = \\sum_{i=1}^{L} I_i $$\nBy the linearity of expectation, the expected total number of sites is:\n$$ E[N_{\\text{NGG}}] = E\\left[\\sum_{i=1}^{L} I_i\\right] = \\sum_{i=1}^{L} E[I_i] = \\sum_{i=1}^{L} \\frac{g^2}{4} = L \\times \\frac{g^2}{4} $$\nNow, we substitute the provided numerical values: $L = 3 \\times 10^9$ and $g = 0.41$.\n$$ E[N_{\\text{NGG}}] = (3 \\times 10^9) \\times \\frac{(0.41)^2}{4} $$\nFirst, calculate the squared term and the fraction:\n$$ \\frac{(0.41)^2}{4} = \\frac{0.1681}{4} = 0.042025 $$\nNext, multiply by the genome length $L$:\n$$ E[N_{\\text{NGG}}] = (3 \\times 10^9) \\times 0.042025 = 0.126075 \\times 10^9 $$\nTo express this result in standard scientific notation ($a \\times 10^b$ where $1 \\le a  10$), we adjust the mantissa and exponent:\n$$ E[N_{\\text{NGG}}] = 1.26075 \\times 10^8 $$\nFinally, the problem requires rounding the answer to three significant figures.\n$$ E[N_{\\text{NGG}}] \\approx 1.26 \\times 10^8 $$\nThis is the final numerical answer for the expected count of \"NGG\" PAM sites on one strand of a genome with the specified characteristics.", "answer": "$$ \\boxed{1.26 \\times 10^{8}} $$", "id": "2802366"}, {"introduction": "Knowing that potential target sites are plentiful, the next challenge is achieving exquisite specificity, which is critical for therapeutic applications where a mutant allele must be corrected while leaving the healthy allele untouched. This practice [@problem_id:5041280] explores the sophisticated strategy of allele-specific targeting, which leverages a deep understanding of the Cas9-DNA interaction. You will apply the \"seed region\" concept—the critical PAM-proximal area where guide-target mismatches are least tolerated—to design a guide RNA capable of distinguishing between two alleles based on a single nucleotide difference.", "problem": "A clinician aims to disrupt a dominant-negative mutant allele using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome editing with Streptococcus pyogenes Cas9 (SpCas9) and a single-guide RNA (sgRNA), while preserving the wild-type allele to maintain normal function. The two alleles differ by exactly one nucleotide within the protospacer sequence. Assume the following foundational facts and definitions:\n- SpCas9 requires a protospacer-adjacent motif (PAM) of sequence $5'$-$\\mathrm{NGG}$-$3'$ immediately downstream of the protospacer on the non-target strand to bind and cleave.\n- SpCas9 uses the sgRNA spacer to form an R-loop by Watson–Crick base pairing to the genomic protospacer beginning at the PAM-proximal end and extending toward the PAM-distal end.\n- The protospacer length is $20$ nucleotides. Number positions within the protospacer as $1,2,\\dots,20$ from the PAM-proximal end ($1$) to the PAM-distal end ($20$).\n- The “seed region” is defined here as positions $1$ through $10$.\n- The PAM sequence $5'$-$\\mathrm{NGG}$-$3'$ is present and identical adjacent to both alleles (that is, PAM availability does not distinguish the alleles).\n\nLet the wild-type allele be $W$ and the mutant allele be $M$. They differ by a single-nucleotide variant at protospacer position $i$, where $1 \\le i \\le 20$. You must choose which allele the sgRNA spacer should perfectly match to maximize selective cleavage of $M$ while sparing $W$, under these constraints.\n\nWhich design choice below is most consistent with the underlying mechanism of target recognition and most likely to achieve strong allele discrimination at the locus, as a function of the position $i$ of the single-nucleotide difference?\n\nA. Choose an sgRNA that perfectly matches $M$, so that the only mismatch (against $W$) is at position $i$; strong discrimination is expected when $i \\in \\{1,\\dots,10\\}$, whereas discrimination is unreliable when $i \\in \\{11,\\dots,20\\}$.\n\nB. Choose an sgRNA that perfectly matches $W$, so that the only mismatch (against $M$) is at position $i$; strong discrimination is expected when $i \\in \\{1,\\dots,10\\}$, whereas discrimination is unreliable when $i \\in \\{11,\\dots,20\\}$.\n\nC. Choose either allele to match; any single mismatch anywhere in the protospacer (any $i \\in \\{1,\\dots,20\\}$) prevents SpCas9 cleavage of the mismatched allele, so strong discrimination is expected regardless of $i$.\n\nD. Do not use spacer mismatches; discrimination cannot be achieved when the PAM is identical for both alleles. Only PAM gain or loss can produce allele selectivity in this scenario.", "solution": "### Derivation of the Correct Strategy\n\nThe fundamental goal is to achieve maximal cleavage of the mutant allele, $M$, and minimal cleavage of the wild-type allele, $W$. The CRISPR-Cas9 system's activity is a function of two primary recognition events: PAM binding and protospacer-sgRNA hybridization.\n\n1.  **PAM Recognition:** The problem states that the PAM sequence ($5'$-$\\mathrm{NGG}$-$3'$) is identical and available adjacent to both the $M$ and $W$ alleles. Therefore, the PAM itself cannot be used as a discriminant. The selectivity must arise from the interaction between the sgRNA and the protospacer.\n\n2.  **Protospacer-sgRNA Hybridization:** To maximize the catalytic activity of Cas9 on a specific target, the sgRNA should be designed to have perfect complementarity with that target's protospacer sequence. Since the objective is to cut the mutant allele $M$, the sgRNA spacer sequence must be a perfect match to the protospacer of allele $M$. Any other design (e.g., matching $W$, or introducing other mismatches) would sub-optimally target $M$, contrary to the primary goal.\n\n3.  **Allele Discrimination via Mismatch:** With an sgRNA designed to perfectly match allele $M$, its interaction with allele $W$ will necessarily involve a single base-pair mismatch at position $i$. The ability of this single mismatch to prevent cleavage of $W$ determines the level of allele discrimination.\n\n4.  **Positional Effect of the Mismatch:** The biophysics of Cas9-sgRNA-DNA interaction dictates that the tolerance to mismatches is not uniform along the protospacer. R-loop formation, the process where the sgRNA displaces one strand of the DNA to form a DNA:RNA hybrid, is the critical step.\n    - The problem correctly states that R-loop formation nucleates at the PAM-proximal end and propagates towards the PAM-distal end.\n    - The initial nucleation and stabilization of the R-loop within the first several bases are critical for the overall binding and subsequent cleavage.\n    - This PAM-proximal region, defined in the problem as the \"seed region\" (positions $1$ through $10$), is exquisitely sensitive to mismatches. A single mismatch in this region is often sufficient to destabilize the initial DNA:RNA hybrid, aborting R-loop propagation and preventing cleavage.\n    - Conversely, the PAM-distal region (positions $11$ through $20$) is more tolerant to mismatches. If the R-loop has successfully formed through the seed region, the system can often accommodate one or more mismatches in the distal part and still proceed to cleave the DNA, albeit sometimes with reduced efficiency.\n\n5.  **Conclusion:** To achieve strong allele discrimination, one must design the sgRNA to be a perfect match to the target allele ($M$) and ensure the resulting mismatch with the non-target allele ($W$) falls within the seed region.\n    - If the single nucleotide difference is at a position $i \\in \\{1, \\dots, 10\\}$ (the seed region), designing an sgRNA perfectly matching $M$ will result in a seed-region mismatch against $W$. This is expected to strongly inhibit cleavage of $W$, leading to high allele specificity.\n    - If the single nucleotide difference is at a position $i \\in \\{11, \\dots, 20\\}$ (the non-seed region), the same sgRNA design will result in a non-seed mismatch against $W$. This mismatch is likely to be tolerated, leading to significant off-target cleavage of the $W$ allele and therefore unreliable or poor discrimination.\n\n### Option-by-Option Analysis\n\n**A. Choose an sgRNA that perfectly matches $M$, so that the only mismatch (against $W$) is at position $i$; strong discrimination is expected when $i \\in \\{1,\\dots,10\\}$, whereas discrimination is unreliable when $i \\in \\{11,\\dots,20\\}$.**\n- **Analysis:** This statement correctly identifies the optimal design strategy and the underlying mechanism. To cleave $M$, the sgRNA should match $M$. The resulting mismatch against $W$ at position $i$ provides discrimination. As derived above, this discrimination is strong when the mismatch is in the seed region ($i \\in \\{1,\\dots,10\\}$) and unreliable when it is in the non-seed, PAM-distal region ($i \\in \\{11,\\dots,20\\}$). This option is fully consistent with the principles of Cas9 targeting.\n\n**B. Choose an sgRNA that perfectly matches $W$, so that the only mismatch (against $M$) is at position $i$; strong discrimination is expected when $i \\in \\{1,\\dots,10\\}$, whereas discrimination is unreliable when $i \\in \\{11,\\dots,20\\}$.**\n- **Analysis:** This strategy is fundamentally flawed. The primary goal is to disrupt allele $M$. Designing an sgRNA that perfectly matches allele $W$ optimizes the system to cleave the very allele that must be preserved. The intended target, $M$, would then be targeted with a mismatch. This would likely lead to inefficient cleavage of $M$, especially if $i \\in \\{1,\\dots,10\\}$. This fails to achieve the primary goal of efficiently disrupting the mutant allele.\n\n**C. Choose either allele to match; any single mismatch anywhere in the protospacer (any $i \\in \\{1,\\dots,20\\}$) prevents SpCas9 cleavage of the mismatched allele, so strong discrimination is expected regardless of $i$.**\n- **Analysis:** This statement makes a factually incorrect claim. It posits that SpCas9 has zero tolerance for any single mismatch across the entire $20$-nucleotide protospacer. Extensive experimental evidence demonstrates that this is false. Mismatches in the PAM-distal half of the protospacer are frequently tolerated. Therefore, discrimination is highly dependent on the position $i$ of the mismatch and is not guaranteed for any $i$.\n\n**D. Do not use spacer mismatches; discrimination cannot be achieved when the PAM is identical for both alleles. Only PAM gain or loss can produce allele selectivity in this scenario.**\n- **Analysis:** This statement is also factually incorrect. While creating a PAM on one allele or disrupting it on another (PAM-based discrimination) is a powerful strategy, it is not the only one. The literature is replete with examples of successful allele-specific editing using sgRNA-protospacer mismatches, particularly when the mismatch is engineered to be in the seed region. The premise of the question is to evaluate this specific, valid mechanism.", "answer": "$$\\boxed{A}$$", "id": "5041280"}, {"introduction": "In real-world applications, especially in clinical settings, selecting the final guide RNA is a complex decision that involves balancing multiple competing factors. A guide that is highly effective at the intended target may also carry unacceptable risks of cutting elsewhere in the genome. This final exercise [@problem_id:5041213] places you in the role of a researcher making a critical choice for a therapeutic application, forcing you to synthesize information about on-target efficiency, off-target risks, PAM compatibility, and expression artifacts to select the safest and most effective candidate.", "problem": "You are designing single guide RNA (sgRNA) candidates for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 editing of a clinically relevant gene in human hematopoietic stem cells. The goal is to correct a pathogenic variant in an exon. You will use Streptococcus pyogenes Cas9 (SpCas9), which requires a protospacer adjacent motif (PAM) of the form NGG and typically shows reduced activity at non-canonical PAMs (for example, NAG). The sgRNA will be expressed from a U6 promoter, which is transcribed by Ribonucleic Acid (RNA) polymerase III and is known to terminate transcription at runs of at least $4$ thymidines in the deoxyribonucleic acid (DNA) template.\n\nFoundational principles to use in your reasoning:\n- Central Dogma: DNA sequence determines the RNA sgRNA sequence; expression constraints (for example, polymerase termination signals) influence sgRNA levels.\n- CRISPR-Cas9 target recognition requires a matching protospacer adjacent to a PAM; canonical NGG PAMs are required for robust SpCas9 activity.\n- Specificity in the genome editing context refers to minimizing off-target cleavage events, especially those in coding exons of other genes, and mismatches of $\\le 2$ nucleotides to the protospacer are of particular concern.\n- Predicted efficiency refers to the likelihood of productive on-target cleavage in the intended cell type; empirical models often report a score in $[0,1]$ or $[0,100]$ scaled units. Extremely high guanine-cytosine (GC) content can increase nonspecific binding, whereas extremely low GC content can reduce target binding; a moderate GC fraction (for example, roughly $40\\%$ to $70\\%$) is often preferred.\n\nYou have four sgRNA candidates targeting the pathogenic exon. For each candidate, a genome-wide in silico guide scoring pipeline has provided the following summaries:\n\n- Candidate A: PAM is NGG; protospacer GC content $= 50\\%$; predicted on-target efficiency score $S_e = 0.72$; predicted off-target sites with $\\le 2$ mismatches $= 3$ total, with $0$ in coding exons; sgRNA has no poly-T ($\\ge 4$ consecutive T) tract.\n- Candidate B: PAM is NGG; protospacer GC content $= 80\\%$; predicted on-target efficiency score $S_e = 0.85$; predicted off-target sites with $\\le 2$ mismatches $= 7$ total, with $2$ in coding exons; sgRNA has no poly-T tract.\n- Candidate C: PAM is NAG; protospacer GC content $= 45\\%$; predicted on-target efficiency score $S_e = 0.60$; predicted off-target sites with $\\le 2$ mismatches $= 1$ total, with $0$ in coding exons; sgRNA has no poly-T tract.\n- Candidate D: PAM is NGG; protospacer GC content $= 55\\%$; predicted on-target efficiency score $S_e = 0.70$; predicted off-target sites with $\\le 2$ mismatches $= 2$ total, with $0$ in coding exons; the protospacer contains a run of $4$ adenines ($\\text{AAAA}$) at positions $9$-$12$.\n\nUnder a clinical protocol that prioritizes patient safety by maximizing specificity (especially avoiding off-targets in coding exons), uses the U6 promoter for sgRNA expression, and still requires reasonable predicted on-target efficiency, which single candidate should be selected?\n\nA. Candidate A\n\nB. Candidate B\n\nC. Candidate C\n\nD. Candidate D", "solution": "The task is to select the optimal single guide RNA (sgRNA) candidate based on a clinical protocol that prioritizes safety, functionality, and efficiency. Each candidate is evaluated against these criteria:\n\n- **Candidate A:** This candidate meets all criteria. The PAM is the canonical NGG, ensuring robust activity. The specificity is high, with zero predicted off-target sites in coding exons, satisfying the primary safety requirement. The sgRNA sequence lacks a poly-T terminator, ensuring proper expression from the U6 promoter. The GC content (50%) and predicted efficiency score (0.72) are both excellent. This is a strong candidate.\n\n- **Candidate B:** This candidate is disqualified due to safety concerns. While it has a high predicted efficiency score (0.85) and the correct NGG PAM, it is predicted to have two off-target sites within coding exons. This poses an unacceptable risk of introducing harmful mutations and violates the protocol's primary emphasis on safety. The high GC content (80%) is also suboptimal.\n\n- **Candidate C:** This candidate is disqualified due to compromised functionality. It targets a site with a non-canonical NAG PAM. *Streptococcus pyogenes* Cas9 shows significantly reduced activity at NAG sites, making the therapeutic outcome unreliable. While its specificity is excellent, the low and unpredictable on-target activity makes it unsuitable for a clinical application.\n\n- **Candidate D:** This candidate is disqualified due to a fatal flaw in sgRNA expression. The protospacer contains an AAAA sequence. This requires the corresponding sgRNA to contain a UUUU tract. A run of four or more uracils in the RNA transcript is a potent termination signal for RNA Polymerase III (which transcribes from the U6 promoter). This will cause premature termination of transcription, leading to little or no functional sgRNA being produced. The candidate is therefore non-functional, despite its other favorable metrics.\n\n**Conclusion:** Candidate A is the only option that satisfies all the key requirements of the clinical protocol. It balances high safety, robust functionality, and strong predicted efficiency.", "answer": "$$\\boxed{A}$$", "id": "5041213"}]}